Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown

@inproceedings{Moss2017VisualCO,
  title={Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown},
  author={Heather E Moss},
  booktitle={Eye and brain},
  year={2017}
}
Multiple sclerosis (MS) is associated with vision changes both due to MS effects on visual pathways and due to medication effects on the visual pathways. Distinguishing the causes of vision change are critical to appropriate diagnosis and management. The incidence, presentation, and treatment of fingolimod-associated macular edema, alemtuzumab-associated thyroid orbitopathy, and progressive multifocal leukoencephalopathy in MS patients are reviewed. Evidence for beneficial effects of acute… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS
2 Extracted Citations
50 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 50 references

FDA Center for Drug Evaluation and Research Summary Review: application number 761029Orig1s000 (Zynbryta/daclizumb); 2016

  • B. Dunn
  • Available from: http://www.accessdata.fda.gov…
  • 2016
2 Excerpts

Similar Papers

Loading similar papers…